Last reviewed · How we verify

Erosive esophagitis — Treatment Landscape & Competitive Intelligence

Erosive esophagitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Erosive esophagitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Dexilant DEXLANSOPRAZOLE Takeda Proton Pump Inhibitor [EPC] (H+, K+)-ATPase 2009-01-01
Nexium esomeprazole AstraZeneca Proton pump inhibitor (PPI) Potassium-transporting ATPase 2001-02-20
Protonix pantoprazole Generic (originally Byk Gulden/Altana/Nycomed) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 2000-02-02
Pantoprazole Sodium Pantoprazole Sodium Pfizer Proton pump inhibitor (PPI) (H+, K+)-ATPase enzyme 2000-01-01
Prevacid lansoprazole Generic (originally Takeda) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10
Prilosec omeprazole AstraZeneca (originally Astra AB) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 1989-09-14
Pepcid famotidine Generic (originally Yamanouchi/Merck) Histamine-2 Receptor Antagonist [EPC] Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2 1986-10-01
Zantac ranitidine GSK (originally Glaxo) H2 receptor antagonist Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor 1983-06-01
Dexilant Dexilant Genuine Research Center, Egypt Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase
Rabeprazole 40 mg rabeprazole-40-mg Pfizer Proton Pump Inhibitor H+/K+ ATPase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Erosive esophagitis
  2. · 2 drugs in Erosive esophagitis
  3. AstraZeneca (originally Astra AB) · 1 drug in Erosive esophagitis
  4. Chang Gung Memorial Hospital · 1 drug in Erosive esophagitis
  5. GSK (originally Glaxo) · 1 drug in Erosive esophagitis
  6. Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Erosive esophagitis
  7. Generic (originally Takeda) · 1 drug in Erosive esophagitis
  8. Generic (originally Yamanouchi/Merck) · 1 drug in Erosive esophagitis
  9. Genuine Research Center, Egypt · 1 drug in Erosive esophagitis
  10. Northern Orthopaedic Division, Denmark · 1 drug in Erosive esophagitis
  11. RenJi Hospital · 1 drug in Erosive esophagitis
  12. Takeda · 1 drug in Erosive esophagitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Erosive esophagitis:

Cite this brief

Drug Landscape (2026). Erosive esophagitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/erosive-esophagitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing